Streetbeat News

HHRS

Hammerhead Energy Inc.

Industry

Crude Petroleum and Natural Gas Extraction

Open

15.17

Mkt cap

1.5B

Volume

High

15.32

P/E Ratio

-46.42

52-wk high

39.30

Low

15.12

Div yield

N/A

52-wk low

6.00

Hammerhead Energy Inc. has received approval from its shareholders and the court for a plan of arrangement with Crescent Point Energy Corp. Under the arrangement, Crescent Point will acquire all issued and outstanding shares of Hammerhead, making it a wholly owned subsidiary. Shareholders will receive $15.50 in cash and 0.5340 of a Crescent Point common share for each Hammerhead share they hold.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 6:03 am

Three energy stocks, Teekay Tankers Ltd. (TNK), Hammerhead Energy Inc. (HHRS), and Ultrapar Participações S.A. (UGP), are considered overbought based on their RSI values, which are above 70. This indicates potential short-term performance issues. TNK recently posted strong quarterly results but saw a slight share price drop. HHRS delivered record production and exceeded type curve assumptions, with a slight share price increase. UGP's stock jumped 25% over the past month and also saw a recent increase in share price.

Portfolio Pulse from Lisa Levin

November 15, 2023 | 12:30 pm

Hammerhead Energy Inc reported an adjusted funds flow from operations (FFO) of C$141.4 million for the third quarter.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 10:41 pm

Hammerhead Energy has agreed to be acquired by Crescent Point Energy for a total consideration of C$21.00 per share. Each Hammerhead share will be exchanged for C$15.50 in cash and C$5.50 in Crescent Point common shares.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:24 pm

RBC Capital analyst Michael Harvey has maintained a 'Sector Perform' rating on Hammerhead Energy (TSX:HHRS) and raised the price target from C$16 to C$18.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 11:55 am

Hammerhead Energy has increased its 2023 annual average production guidance, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 7:10 pm

Hammerhead Energy has increased its 2023 annual average production guidance to 41,500 boe/day, up from the previous estimate of 40,200 boe/day. This comes after the company's 12-well North Karr 10-14 pad exceeded internal forecasts, with peak pad production exceeding 17,800 boe/d. As a result, Hammerhead's corporate production volumes for August averaged 48,500 boe/d.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 10:06 am

The article lists the stocks that have gained and lost the most in Thursday's mid-day session. Acer Therapeutics Inc. (ACER) shares jumped 145% after Zevra Therapeutics announced it will acquire the company. 1847 Holdings LLC (EFSH) surged 66.6% after reporting successful restructuring of promissory notes. iCoreConnect Inc. (ICCT) climbed 51.7% after announcing the closing of its business combination with FG Merger Corp. On the other hand, Axcella Health Inc. (AXLA) shares dipped 29.1%, AgileThought, Inc. (AGIL) shares fell 27.7%, and Lands' End, Inc. (LE) declined 22.4% after reporting worse-than-expected second-quarter results and issuing weak guidance.

Portfolio Pulse from Lisa Levin

August 31, 2023 | 4:50 pm

RBC Capital analyst Michael Harvey has maintained a 'Sector Perform' rating on Hammerhead Energy (TSX:HHRS) and raised the price target from C$13 to C$14.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 2:30 pm

Several stocks experienced significant movement in Thursday's mid-day session. Sigilon Therapeutics (SGTX) shares climbed 523.8% after Eli Lilly agreed to acquire the company. Eco Wave Power Global (WAVE) gained 47.4% after announcing plans for a share repurchase program. Franklin Covey Co. (FC) gained 25.2% following upbeat Q3 results. Carriage Services (CSV) surged 24.4% after its Board initiated a process to explore potential strategic alternatives. The Greenbrier Companies (GBX) gained 23.2% after reporting better-than-expected Q3 results and raising FY23 revenue guidance. On the downside, BioXcel Therapeutics (BTAI) shares dipped 62.2% after releasing topline results from a Phase 3 trial.

Portfolio Pulse from Lisa Levin

June 29, 2023 | 5:52 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.